How to Qualify for GLP-1

Summary: FDA approves GLP-1s for adults with BMI 30 and over, or BMI 27 and over with at least one weight-related condition like hypertension, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease. Insurance plans usually add prior authorization, documented diet attempts, and step therapy on top.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: to qualify for a GLP-1 prescription, you need to meet the FDA criteria on the drug's label. For weight loss with Wegovy or Zepbound that means a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease ^[1][2]. For type 2 diabetes with Ozempic or Mounjaro, the qualifier is a diabetes diagnosis, typically an A1C of 6.5% or higher under ADA criteria ^[3][5].

Insurance is a separate hurdle. Plans almost always layer prior authorization, documented lifestyle attempts, and step therapy on top of the FDA criteria. The FDA tells you whether you can legally be prescribed the drug. Your insurer tells you whether they will pay for it. Two different yes-or-no questions.

The two FDA pathways for weight loss

The FDA labels for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) both use the same two-tier model. You qualify if you fall into either tier.

The accepted comorbidities on the FDA label and on virtually every payer policy are:

• Type 2 diabetes
• Hypertension (typically defined as 130/80 mmHg or higher, or current antihypertensive use)
• Dyslipidemia, meaning elevated LDL, total cholesterol, or triglycerides
• Obstructive sleep apnea, documented by polysomnography or a CPAP prescription
• Cardiovascular disease, including prior heart attack, stroke, or documented atherosclerosis

A few payer formularies also accept polycystic ovary syndrome with insulin resistance and non-alcoholic fatty liver disease (now often called MASLD). Those two are not on every plan's qualifying list, so check the formulary before you assume they count.

Wegovy is the only GLP-1 currently approved for adolescents aged 12 to 17 who meet the obesity criteria ^[1]. Zepbound, oral semaglutide, and orforglipron are adult-only.

The FDA pathway for type 2 diabetes

If you have type 2 diabetes, you do not need to clear a BMI threshold to qualify for Ozempic, Mounjaro, Rybelsus, or any other diabetes-indicated GLP-1. The qualifier is a documented type 2 diabetes diagnosis. The ADA defines that as any one of the following ^[3]:

• A1C of 6.5% or higher
• Fasting plasma glucose of 126 mg/dL or higher
• A two-hour plasma glucose of 200 mg/dL or higher during an oral glucose tolerance test
• Random plasma glucose of 200 mg/dL or higher in a patient with classic hyperglycemia symptoms

Each result, except the symptomatic one, should be confirmed by a repeat test on a separate day before a clean diagnosis is recorded.

Prediabetes (A1C 5.7 to 6.4%, fasting glucose 100 to 125 mg/dL) does not on its own qualify you for an FDA-approved diabetes GLP-1, but it does count as a metabolic comorbidity that pairs with a BMI of 27 to 29.9 to unlock the weight-loss pathway with Wegovy or Zepbound.

How to document a qualifying comorbidity

Insurance prior authorizations live and die on documentation. A clinician saying "I observed hypertension" is rarely enough. Payers want the lab value, the diagnosis code, and the date.

Have these in your chart before the prior auth goes in. Asking the doctor to "fill in something" three days into the auth review is the slowest way to get approved.

Insurance criteria run stricter than FDA

The FDA criteria are the floor. Private payers and employer plans stack additional requirements on top, and those requirements are what actually decide whether you start the medication this month or in six months.

The most common payer add-ons:

• Prior authorization. Your prescriber submits a form with your BMI, comorbidities, prior weight loss attempts, and labs. Approval is not automatic.
• Documented prior weight loss attempts. Many plans require evidence of three to six months of structured diet and exercise, often through a specific program (Weight Watchers, Noom, hospital-based program). "I tried to eat less" is not documentation.
• Step therapy. You may be required to try and fail a cheaper anti-obesity drug first, such as phentermine, orlistat, or naltrexone-bupropion (Contrave).
• BMI re-verification. A current weight from within the last 30 to 90 days, taken in the prescriber's office, not self-reported.
• Enrollment in a lifestyle program. Some plans require concurrent enrollment in a behavior-change program for as long as the GLP-1 is dispensed.

The Affordable Care Act does not mandate coverage of anti-obesity medications, so self-funded employer plans have full discretion. Plenty of employers simply exclude weight-loss drugs from coverage entirely, even when they cover Ozempic and Mounjaro for diabetes. If your plan's formulary lists Wegovy or Zepbound as "non-formulary excluded," no amount of clinical documentation will get them covered. You either change plans at open enrollment, pay cash, or go a different route.

Medicare's GLP-1 Bridge starting July 2026

Medicare historically refused to cover weight-loss drugs under the Part D statute. That changes on July 1, 2026, when the Medicare GLP-1 Bridge program launches, running through December 31, 2027 ^[4]. Beneficiaries who qualify pay a flat $50 per month copay for Wegovy (injection or oral), Zepbound KwikPen, or Foundayo. The copay does not count toward the Part D out-of-pocket cap.

Three eligibility tiers, you only need to meet one:

The prior authorization is submitted to a central CMS processor, not to your individual Part D plan. Your starting BMI counts, not your current BMI, so if you started GLP-1 therapy at BMI 37 and have since dropped to 33, you still qualify under Tier 1.

The "BMI 27 and a condition" route in detail

This is the route most people in the overweight range take, and it is also where the most prior auth denials happen because the comorbidity is poorly documented. A few specifics that catch people out.

BMI 27 means 27.0 on the day of the prior auth, not 27.0 three years ago. If you have dropped to BMI 26.8 by losing 5 pounds before the appointment, you no longer qualify on paper. Some clinics weigh patients fully dressed and add a pound or two; others have you remove shoes. The number on the chart is the number the payer evaluates.

A single elevated cholesterol reading is usually enough for dyslipidemia coding, but the lipid panel must be in the chart. A patient saying "my cholesterol is high" does not move a prior auth.

Hypertension counts even if it is well-controlled on medication. If you are taking lisinopril and your blood pressure is now 120/80, you still carry the hypertension diagnosis and you still qualify. The payer cares about the diagnosis code, not your current numbers.

Sleep apnea documentation must be formal. Snoring loudly does not count. Daytime sleepiness does not count. A sleep study with an apnea-hypopnea index above the diagnostic threshold (usually AHI of 5 or higher with symptoms, or 15 or higher without) is what counts. A CPAP prescription is also accepted.

What about BMI without a comorbidity?

If your BMI is below 27 and you have no weight-related condition, you do not qualify for an FDA-indicated GLP-1 weight-loss prescription. This is the most common reason cash-pay telehealth platforms get cited by state medical boards: prescribing GLP-1s for cosmetic weight loss to patients who do not meet the label criteria is off-label and increasingly being scrutinized.

There is no GLP-1 without BMI requirements for weight loss, despite what some marketing pages suggest. The "no BMI requirement" framing usually means one of two things: the platform prescribes for type 2 diabetes (where BMI is not a qualifier) or the platform is prescribing off-label and accepting the regulatory risk that comes with it. Be skeptical of any provider that says BMI does not matter for a weight-loss prescription. It matters to the FDA and it matters to your insurer.

BMI categories and where "morbidly obese" sits

The standard adult BMI categories used by the WHO, CDC, and every payer formulary:

"Morbidly obese" is older terminology, now usually replaced with "class III obesity" or "severe obesity" in clinical writing. The threshold is BMI 40, or BMI 35 with a serious obesity-related condition. That cutoff also happens to be the standard threshold for bariatric surgery referral.

BMI vs body fat, and where BMI falls short

BMI is a screening tool. It uses height and weight and nothing else, so it overestimates body fat in muscular people and underestimates it in older adults who have lost muscle mass. It also performs differently across ethnic groups. WHO consultations have noted that Asian populations carry a higher cardiometabolic risk at lower BMI values, with some clinical guidelines recommending obesity thresholds of BMI 27.5 rather than 30 for South Asian, East Asian, and Southeast Asian patients.

For US prescribing, BMI 30 and BMI 27 are still the operational thresholds. Body fat percentage, waist circumference, and DEXA scans can supplement a prior auth that is borderline, but they do not replace the BMI number on the FDA label. Waist circumference of 40 inches or more in men and 35 inches or more in women is recognized as a marker of elevated metabolic risk and can strengthen a borderline auth, but it is not a standalone qualifier.

What to do if you do not qualify

Falling outside the FDA criteria does not mean nothing works. The conventional alternatives, in order of escalation:

1. Structured nutrition and exercise. A registered dietitian, a Mediterranean or DASH dietary pattern, resistance training twice a week, and a step count target are still the foundation of long-term weight loss. Not glamorous, still effective for many people, and the only intervention recommended below BMI 27.
2. Non-GLP-1 anti-obesity medications. Phentermine (short-term), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Xenical, Alli) are FDA-approved for chronic weight management at BMI 30 or BMI 27 with a comorbidity. Effect sizes are smaller than GLP-1s, but coverage is often easier and cash prices are lower.
3. Bariatric surgery. Sleeve gastrectomy and Roux-en-Y gastric bypass are indicated at BMI 40, or BMI 35 with significant comorbidities. Average weight loss exceeds what GLP-1 medications produce, with durable metabolic benefits in trials going out 20 years.
4. Re-evaluation later. If you gain enough weight to cross BMI 27 with a documented comorbidity, or BMI 30 alone, you qualify and can revisit the GLP-1 conversation. Some patients prefer to address sleep apnea or hypertension first, document the diagnosis, and then revisit eligibility from a stronger position.
5. Treat the underlying driver. Hypothyroidism, PCOS, depression, sleep deprivation, certain antidepressants, certain antipsychotics, and steroid courses all push weight up. Treating those first sometimes resolves enough of the weight problem that GLP-1 is no longer the right tool.

What the consultation looks like

A real prescribing visit, whether in person or via telehealth, covers the same ground:

1. Intake form. Height, weight, medical history, current medications, allergies, family history. The form screens for contraindications before the visit so the clinician does not waste your time.
2. BMI calculation. Done in the office or from your reported values. The calculated number lands in your chart.
3. Comorbidity screen. A1C, fasting glucose, blood pressure, lipid panel, plus any active diagnoses already in your chart.
4. Contraindication review. Personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, prior pancreatitis, current pregnancy or breastfeeding, severe gastroparesis. These are the absolute no-go conditions on every GLP-1 label ^[1][2].
5. Goals discussion. Total weight loss target, time horizon, what you have tried before, willingness to inject weekly for a long time.
6. Prescription decision. If you qualify and have no contraindications, the prescription goes to your pharmacy. If insurance is involved, the prior auth packet is built and submitted that day or the next.

The "two-minute online quiz" model that some telehealth platforms use compresses steps 1 through 6 into a questionnaire and a video visit. The criteria are still the criteria. A responsible telehealth platform applies the FDA thresholds. An irresponsible one waves them through.

Common questions about GLP-1 qualification

What BMI do I need to qualify for a GLP-1?

BMI of 30 or higher qualifies on BMI alone for Wegovy or Zepbound. BMI of 27 to 29.9 qualifies if you also have at least one weight-related condition like hypertension, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease.

Can I qualify for a GLP-1 at BMI 27?

Yes, if you have at least one documented weight-related comorbidity. The qualifying conditions on the FDA label are hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease. BMI 27 with no comorbidity does not qualify under the FDA criteria.

Is there a GLP-1 without a BMI requirement?

Not for weight loss. Ozempic, Mounjaro, and Rybelsus are prescribed for type 2 diabetes without a BMI cutoff, but the qualifier is the diabetes diagnosis itself. Any platform offering weight-loss GLP-1 "without BMI requirements" is prescribing off-label.

What A1C qualifies for a diabetes GLP-1?

6.5% or higher meets the ADA diagnostic criterion for type 2 diabetes. Fasting glucose of 126 mg/dL or higher, or a two-hour OGTT of 200 mg/dL or higher, also qualifies. Confirm with a repeat test on a separate day.

What BMI is considered morbidly obese?

40.0 or higher is class III obesity, the modern term for what was previously called morbid obesity. BMI 35 with a serious obesity-related condition also falls in this severe category and is the standard threshold for bariatric surgery referral.

What insurance documentation will I need?

A current weight and calculated BMI from a recent office visit, lab work supporting any comorbidity (A1C, lipid panel, blood pressure log), and often three to six months of documented prior weight-loss attempts. Some plans also require enrollment in a lifestyle program and a step-therapy trial of a cheaper drug.

Does PCOS qualify me for a GLP-1?

PCOS is not on the FDA label as a qualifying comorbidity, but PCOS often presents with insulin resistance and BMI above 27, which together qualify you under the standard weight-loss pathway. Some payer policies accept PCOS with insulin resistance directly.

What if my insurance refuses to cover a GLP-1?

Options include appealing the denial with additional documentation, switching to a cheaper non-GLP-1 weight medication, paying cash for a compounded version (typically $200 to $500 per month), or using a manufacturer savings card. Brand-name pens cash-pay run around $1,000 to $1,350 per month without coverage.

Will Medicare cover a GLP-1 for weight loss?

Starting July 1, 2026, the Medicare GLP-1 Bridge will cover Wegovy, Zepbound KwikPen, and Foundayo at a flat $50 per month copay for beneficiaries who meet one of three eligibility tiers (BMI 35+, BMI 30+ with specific conditions, or BMI 27+ with specific conditions).

Can I qualify if I have a family history of thyroid cancer?

Medullary thyroid carcinoma in a personal or family history is an absolute contraindication on the FDA boxed warning. Other thyroid cancers (papillary, follicular) are not contraindications. Discuss the specific cancer type with your prescriber before assuming you are excluded.

What this article does not cover

This page is the qualification framework: who is eligible, what documentation matters, and where insurance criteria diverge from the FDA criteria. Adjacent questions, like which specific telehealth platform has the fastest approval turnaround, what compounded GLP-1 costs in your state, and how to handle a denied prior authorization, have their own dedicated pages on this site. Use the search or the sidebar to find them.